Chronic Granulomatous Disease Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Chronic Granulomatous Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Evaluation of Patients With Immune Function Abnormalities

Chronic Granulomatous Disease (CGD)X-Linked Severe Combined Immune Deficiency (XSCID)Leukocyte Adhesion Deficiency 1 (LAD)+1 more
National Institute of Allergy and Infectious Diseases (NIAID)3,500 enrolled1 locationNCT00128973
Recruiting
Phase 1Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Chronic Granulomatous Disease
National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT05463133
Recruiting
Phase 1Phase 2

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Chronic Granulomatous Disease (CGD)X-Linked Chronic Granulomatous Disease
National Institute of Allergy and Infectious Diseases (NIAID)10 enrolled1 locationNCT06325709
Recruiting
Phase 1Phase 2

Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis

Chronic Granulomatous Disease-associated Colitis
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT05333471
Recruiting
Phase 1Phase 2

Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease

X-Linked Chronic Granulomatous Disease
Ensoma15 enrolled9 locationsNCT06876363
Recruiting
Phase 1

NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

InfectionChronic Granulomatous Disease
National Institute of Allergy and Infectious Diseases (NIAID)25 enrolled1 locationNCT05189925
Recruiting

Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

Chronic Granulomatous Disease (CGD)
Ensoma60 enrolled52 locationsNCT06605378
Recruiting
Phase 2

Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD

Chronic Granulomatous Disease X-linked (X-CGD)
IRCCS San Raffaele3 enrolled2 locationsNCT03055247